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Stem cell biology holds great promise for a new era of cell-based therapy, sparking considerable interest
among scientists, clinicians, and their patients. However, the translational arm of stem cell science is in a rela-
tively primitive state. Although a number of clinical studies have been initiated, the early returns point to
several inherent problems. In this regard, the clinical potential of stem cells can only be fully realized by
the identification of the key barriers to clinical implementation. Here, we examine experimental paradigms
to address the critical steps in the transition from stem cell biology to regenerative medicine, utilizing cardio-
vascular disease as a case study.Few would argue with the sentiments of Charles Spurgeon
(1834–1892), the leading preacher of Victorian England, who
professed that ‘‘every generation needs regeneration.’’ In our
modern era of stem cell biology, these words have taken on a
new meaning, especially for the millions of patients afflicted
with chronic diseases for which there is neither a cure nor further
available treatment options. In this regard, the almost monthly
major advances in stem cell biology have created an aura of
excitement and hope in both the scientific and medical commu-
nities, resulting in a sense of urgency to move new developments
quickly into the clinical setting. This translational dream has been
further boosted by the announcement earlier this year that the
United States’ Food and Drug Administration (FDA) are consid-
ering the approval of the world’s first clinical trial using human
embryonic stem cell (ESC)-derived cells in an attempt to find
a remedy for spinal cord injuries (Couzin, 2009).
With respect to cardiovascular disease, literally hundreds of
clinical studies have examined the potential therapeutic effects
of heart stem cell therapy. A quick Google search yields over
2.5 million separate listings for heart stem cell therapy, with
many overseas centers already offering routine treatment for
advanced forms of heart failure often for sums ranging upwards
of 50,000 US$ per treatment (reviewed in (Lau et al., 2008)). At
the same time, the bulk of the clinical data to date suggests
that these are relatively early days for cell based therapy for heart
disease, with a number of negative, marginal, and transient
effects recorded in larger scale double-blind placebo controlled
trials. Ironically, the major import of these studies is in pointing
out specific clinical roadblocks, including the identification of
the optimal cell type, ideal in vivo delivery system, novel
approaches to promote the conversion to fully functional, mature
cardiac muscle, integrated vascularization, and the appropriate
alignment and electrical integration with the recipient myocar-
dium (for review, see (Chien, 2008; Chien et al., 2008). Given
the above, the question arises as to exactly where we are on
the translational road map from cardiovascular stem cell biology
to heart stem cell therapy. At this moment, are we headed in the364 Cell Stem Cell 5, October 2, 2009 ª2009 Elsevier Inc.right direction, taking a tangential course, reaching a fork in the
road, or simply ‘‘lost in translation’’ (Chien, 2004)? If the latter
is the case, how do we get back on track and what are the critical
issues that must be addressed to correct our course? In this
review, we utilize studies of regenerative cardiovascular therapy
as a paradigm to identify critical issues for stem cell therapeutics
in other organ systems, with the long range view that a common
core set of problems must be solved to unlock the potential of
stem cell biology for regenerative therapy.
Scalability and Heart Stem Cell Therapy
Cardiovascular disease is the leading cause of death in the world
today (Lopez et al., 2006). Specifically, myocardial infarction is
the leading cardiovascular cause of mortality, and in cases
where it does not lead to sudden death, it frequently injures a
large enough proportion of the cardiomyocytes of the heart to
diminish its contractile capacity below a critical threshold. This
damage leads to heart failure, a condition where almost half of
the affected patients die within one year from the onset of symp-
toms - a grimmer prognosis than in many forms of cancer
(Jessup and Brozena, 2003). Effective treatment of heart failure
is the holy grail of regenerative cardiology, and the conceptual
framework regarding therapy is quite simple - stem cells would
be used in a replacement setting, thereby replenishing tissue
lost as a result of disease. There is no question that this approach
is a highly meritorious area of investigation, but, at the same time,
there are some important barriers that need to be addressed to
allow stem cell-mediated repair to become clinical reality.
One frequently underestimated challenge in regenerative
medicine is the sheer number of cells that needs to be replaced.
The most common cause of heart failure is a myocardial infarc-
tion caused by an occlusion of the left anterior descending coro-
nary artery, supplying the left ventricle of the heart with freshly
oxygenated blood. The outcome is a loss of cardiomyocytes,
accompanied by the formation of a fibrous scar, resulting in
decreased pumping capacity of the heart. In a typical myocardial
infarct it is estimated that one billion cardiomyocytes are lost
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cells in perspective, it is approximately equivalent to one
hundred standard 10 cm tissue culture dishes of cells. Although
an improvement of cardiac function can be achieved without
replacing all lost cells, it is evident that stem cell-derived treat-
ment of heart failure will have to be based on a cellular system
permitting the isolation of sufficient number of cells to generate
hundreds of millions of cardiomyocytes upon transplantation
for a single patient. In considering the prevalence of heart failure
world wide, and its recent exponential increase, the challenge of
the scalability of heart stem cell therapy, as well as that of other
tissues, is a considerable, and often overlooked, challenge
(Kirouac and Zandstra, 2008). The clinical therapeutic paradigm
will have to be sufficiently robust, scalable, and effective to be
adopted widely.
Sources of Autologous Cell-Based Therapy for Cardiac
Disease: Blood and Skeletal Muscle Progenitors?
The first experimental attempts to use regeneration to restore
cardiac function in an injured myocardium focused on two
extra-cardiac sources of cells: progenitors from skeletal muscle
and bone marrow. Although both these sources are clearly not
authentic heart stem cells, they address the problem of an
accessible, scalable cell type, i.e., an autologous stem cell
source capable of generating a sufficient number of cells to
potentially match the cell loss after myocardial infarction.
The first approach was to transplant satellite cells, skeletal
muscle-specific stem cells (‘‘myoblasts’’), to the injured heart,
with the hope that the cardiac microenvironment would promote
the transdifferentiation of myoblasts into cardiomyocytes with
a resultant increase in contractile capacity. Unfortunately, exper-
iments in rodents showed that even though satellite cells trans-
planted to infarcted hearts of syngenic hosts survived and
matured to fully differentiated skeletal muscle fibers, there was
no evidence of conversion to a cardiomyocyte fate (Reinecke
et al., 2002). Furthermore, the engrafted cells did not exhibit
electromechanical coupling with the cardiomyocytes of the
host myocardium, but functioned in isolation from the native
cardiac tissue (Rubart et al., 2004). However, several groups
reported a positive effect on heart function in rodent (Taylor
et al., 1998) and larger animal (Ghostine et al., 2002) models of
myocardial infarction. The mechanistic basis for such a beneficial
effect is not fully understood, but may be due to an increased
stiffness of the ischemic area of the ventricular wall from the
simple increase in cell mass, or the release of paracrine factors
from the grafted cells that somehow provide a positive effect
for the injured heart. Despite the lack of mechanistic under-
standing regarding their mode of action, a phase I clinical trial
that transplanted satellite cells to the hearts of patients with
chronic heart failure was initiated eight years ago (Menasche
et al., 2001). A subsequent, more in-depth study (randomized,
double blind, placebo controlled, with several centers partici-
pating) failed to show improvement in several key parameters
of cardiac function after a follow-up period of six months (Mena-
sche et al., 2008). What might explain this disappointing result,
given the encouraging data obtained using animal models?
Clearly, the mouse offers many advantages as a model system,
including transgenesis, many different genetic backgrounds,
and a comparatively low cost. However, several important differ-ences are equally clear when human and mouse cardiovascular
systems are compared, including parameters such as heart rate,
oxygen consumption, properties of the coronary arteries, and
response to input from innervation and circulating regulatory
peptides (Dixon and Spinale, 2009). Furthermore, most injury
models used commonly in mice do not capture all aspects of
the pathobiology of human disease, and frequently result in a
thin fibrous cap/aneurysm where any cell of interest might
have a benenficial effect by simply augmenting the chamber
wall mass and secondarily improving function by decreasing
wall stress. Consequently, a word of caution is warranted
when extrapolating data from mouse models to human patients,
and moving to a larger animal model for validating data obtained
in mice is necessary. In the cardiovascular field, candidate
models include sheep, dog and pig models of cardiac pathology
(Dixon and Spinale, 2009). The physiology of the cardiovascular
system in these model organisms more closely resemble the
human. However, as evident from the above, even encouraging
data from experiments in larger animal models do not neces-
sarily translate to a successful outcome in clinical trials. An
inescapable conclusion is that positive therapeutic effects of
cell-based therapy in small and large animal models of myocar-
dial infarction may not be predictive of clinical success. In short,
there is a need for better validated animal model systems for
cardiac regenerative therapy.
An alternative strategy to using skeletal muscle has been to
transplant bone marrow cells to the injured heart. Over a decade
ago, several research groups reported that populations of autol-
ogous stem cells, including bone marrow stem cells, appeared
to possess a considerably higher degree of developmental
potential than previously appreciated (reviewed in (Morrison,
2001)). Upon transplantation, such bone marrow-derived cells
were reported to give rise to differentiated progeny in several
solid organs, including the heart. Given the relative accessibility
of bone marrow, this finding spurred researchers to study the
fate of bone marrow stem cells upon transplantation in rodent
models of myocardial infarction, reporting a robust transdifferen-
tiation of injected bone marrow cells to cardiomyocytes (Jack-
son et al., 2001; Orlic et al., 2001). Enthusiasm in the field was
further boosted by a report examining postmortem tissue from
patients that had received a heart transplant. In female donor
hearts transplanted to male recipients, Y-chromosome-positive
cardiomyocytes were detected, indicating cellular chimerism of
the transplanted heart (Quaini et al., 2002). Similar findings, albeit
with a much lower frequency of cardiac chimerism, were re-
ported by other groups, including one study examining cardiac
tissue in patients receiving bone marrow transplants (Deb
et al., 2003). However, several groups have since contested
the original claims that bone marrow cells can efficiently transdif-
ferentiate to a cardiomyocyte fate (Balsam et al., 2004; Murry
et al., 2004). Subsequent studies have documented that what
originally was interpreted as transdifferentiation may indeed
have been the result of cell fusion events, where transplanted
cells fuse with differentiated cardiac cells in the recipient
(Alvarez-Dolado et al., 2003; Nygren et al., 2004; Terada et al.,
2002). It is widely accepted by the stem cell community at large
that cell fusion events, such as these, do not generate new differ-
entiated progeny in other organ systems, and by analogy it is
unlikely that new cardiomyocytes are being generated by fusionCell Stem Cell 5, October 2, 2009 ª2009 Elsevier Inc. 365
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Trial No. Cell Type Absolute LVEF% D LVEDV D LVESV D
REPAIR-AMI
(Schachinger et al., 2006)
204 BMC +2.5 (4 mon) N.S. (4 mon) N.S. (4 mon)
ASTAMI (Lunde et al., 2006) 100 BMC N.S. (6 mon) N.S. (6 mon) N.R.
Janssens et al.
(Janssens et al., 2006)
67 BMC N.S. (4 mon) N.S. (6 mon) N.S. (6 mon)
BOOST (Wollert et al., 2004) 60 BMC +6.0 (6 mon); N.S. (18 mon) N.S. (6 mon); N.S. (18 mon) N.S. (6 mon); N.S. (18 mon)
Meluzin et al. (Meluzin et al., 2008) 60 BMC +6.0 (3 mon); +7.0 (12 mon) N.S. (3, 6, 12 mon) N.S. (3, 6, 12 mon)
TOPCARE-AMI
(Schachinger et al., 2004)
59 BMC +8.3 (4 mon); +9.3 (12 mon) N.S. (4 mon) 10 cc (4 mon)
MAGIC (Menasche et al., 2008) 97 SMB N.S. (6 mon) N.S. (6 mon) 8.3 cc/m2 (6 mon)
Chen et al. (Chen et al., 2004) 69 BMSC +14.0 (3 mon); +13.0 (6 mon) 38 cc (3 mon) 18 cc (3 mon)
MAGIC CELL-3-DES
(Kang et al., 2006)
82 PBSC +5.1 (6 mon for AMI) N.S. (6 mon) N.S. (6 mon)
van Ramhoorst et al.
(van Ramshorst et al., 2009)
50 BMC +3 (3 mon) N.S. (3 mon) N.S. (3 mon)
The following abbreviations are used: BMC, bone marrow stem cell; SMB, skeletal myoblast; BSMC, bone marrow mesenchymal stem cell; PBSC,
peripheral blood stem cell; LVEF% D, left ventricular ejection fraction, percent difference; LVEDV D, left ventricular end diastolic volume, difference;
LVESV D, left ventricular end systolic volume, difference; mon, months follow up after treatment; AMI, acute myocardial infarct; N.S., not significant;
and N.R., not recorded.events. Taking this unexpected finding into account, previously
published reports may have to be re-evaluated, and there is
currently no consensus on whether bone marrow cells have
the capacity to transdifferentiate into the cardiac lineage upon
transplantation. Nonetheless, clinical trials using bone marrow
infusion in cases of acute myocardial ischemia as well as chronic
heart failure have been initiated, with the first pilot study reported
seven years ago (Strauer et al., 2002). The outcomes of these
trials have been somewhat conflicting, with some trials showing
a beneficial effect, whereas others have failed to see statistically
significant differences compared to the control group. Again, any
positive effect from such treatment has been attributed to a
poorly understood paracrine effect, possibly by direct effect on
the myocardium or by contributing to increased vascularization
of the heart. Studies have identified a number of putative para-
crine factors that might be responsible, including VEGF, FGF,
IGF, and SDF (Gnecchi et al., 2005; Kinnaird et al., 2004; Uemura
et al., 2006).
Taken together, clinical trials using bone marrow and satellite
cells (summarized in Table 1) indicate that both these sources
of cells may have some modest effects when administered to
the failing heart. At the same time, the effects clearly cannot be
ascribed to cardiac regeneration. The fact that the injection of
many cell types have been reported to transiently improve
cardiac function in animal model systems following myocardial
infarction, including, adipose tissue stromal cells (Li et al.,
2007), bone marrow (Orlic et al., 2001), circulating putative endo-
thelial progenitors with features of circulating monocytes (Kocher
et al., 2001), skeletal myoblasts (Taylor et al., 1998), and even
undifferentiated embryonic stem cells themselves (Min et al.,
2002), suggests that the simple short term improvement in
cardiac function cannot be taken as direct evidence of cardiac
regeneration per se. Moreover, a portion of the effect may relate
to effects of decreasing wall stress by increasing the tissue mass
in a thinning myocardial wall, an anatomic effect that is indepen-366 Cell Stem Cell 5, October 2, 2009 ª2009 Elsevier Inc.dent of a real regenerative effect. Accordingly, a parallel search
for identifying populations of stem cells with innate cardiomyo-
genic potential, i.e., authentic endogenous cardiac progenitor
cells seems warranted.
Mobilization of Endogenous Cardiac Progenitor Cells
Promoting the mobilization of a putative endogenous pool of
cardiac progenitors in the adult human heart would represent
an alternative to replacing lost cardiomyocytes by transplanta-
tion. In this manner, the concept would be to activate the endog-
enous heart regenerative machinery, a process akin to boosting
erythrocyte levels with erythropoietin. In this paradigm, the
potential problems associated with the surgical procedure,
in vitro culturing of cells for grafting, immunological incompati-
bility, and so forth, are avoided.
Cardiac regeneration has been documented in at least two
vertebrate species, newt and zebrafish, where cardiac injury
elicits a regenerative response characterized by cell cycle re-
entry and dedifferentiation of cardiomyocytes (Oberpriller and
Oberpriller, 1974), or mobilization of a tissue-specific, undiffer-
entiated progenitor population (Lepilina et al., 2006; Poss et al.,
2002), respectively. In contrast, the notion that cardiac tissue
in mammalian species would have any potential for regeneration
has been very controversial. However, three recent publications
provide compelling evidence that there is a finite level of cardio-
myocyte turnover in the mammalian heart. Lineage tracing in a
mouse mutant with an X-linked mutation revealed a striking
regenerative capacity in the fetal heart, indicating that healthy
cardiac cells can increase their rate of proliferation and thereby
compensate for a 50% loss of cardiac tissue (Drenckhahn
et al., 2008). By combination of a cardiac injury model with
genetic fate mapping, it was shown that the adult mouse heart
also displays some regenerative capacity, albeit to a lesser
extent (Hsieh et al., 2007). Through use of radiocarbon dating
of human postmortem cardiac tissue, a recent elegant study
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human heart (Bergmann et al., 2009). As in the mouse, a decline
in regenerative capacity was observed with increased age, in
that cardiomyocyte turnover ranged from a rate of 1% per year
in young adults to 0.5% in the elderly. Importantly, although
the endogenous regenerative potential of the adult mammalian
heart appears to be quite limited, and clearly is not sufficient to
cope with the widespread death of cardiomyocytes seen in
a myocardial infarction, these findings indicate either an unex-
pected degree of self-renewal of adult cardiomyocytes, or a
potential source of endogenous stem cells with cardiogenic
potential. In this regard, published studies from several groups
identify minute numbers of putative cardiac stem cells in the
adult heart, as defined phenotypically by cell-surface markers
such as c-kit (Beltrami et al., 2003), Sca-1 (Oh et al., 2003), or
other characteristics (Hoechst dye exclusion [Martin et al.,
2004]). These cells were found to proliferate and generate new
cardiomyocytes in culture, and in some cases even improve
cardiac function upon transplantation (reviewed in Martin-Puig
et al., 2008).
Unfortunately, there are several caveats that currently
preclude the ultimate utility of adult, cardiac-specific stem cells
in regenerative medicine. First of all, to date, there is no con-
sensus on how to identify these cells, and their role as authentic
endogenous heart progenitors will rest upon documenting
that they are recruited to the site of injury, undergo expansion,
and subsequently convert to authentic cardiomyocytes. This
achievement will ultimately require conditional lineage tracing
in the setting of cardiac injury, and such a tracing is a technically
feasible but challenging experimental paradigm that has not yet
been fully accomplished with any cell type. Different molecular
markers have been suggested as identifiers of adult cardiac
stem cells, but the expression of these proteins vary from study
to study, do not overlap, and have not always been reproducible.
Second, the biology of such putative adult cardiac progenitor
cells is hitherto largely unknown. The molecular mechanisms
promoting their self-renewal and differentiation into the different
lineages of the heart have not been identified, and lineage-
tracing experiments providing evidence that they contribute to
the generation of new cardiac cells in the adult are lacking.
Although mobilization of endogenous cardiac stem cells after
injury may be an important strategy for treating heart failure in
the future, in the short term it is very difficult to envision whether
a sufficient level of mobilization would be capable of meeting the
numeric demand for cell-replacement therapy after myocardial
infarction.
Lineage Tracing and the Direct Identification
of Authentic Endogenous Heart Progenitors
As a result of the challenges that currently prevent the harness-
ing of endogenous cardiac progenitors, the focus of the field is
beginning to shift to stem cells with proven cardiac potential,
converging on the developmental biology of cardiogenesis.
Recent advances in developmental biology have been used for
identification of cardiac stem cells in the embryonic and fetal
heart. During embryogenesis, two anatomically distinct groups
of cells of mesodermal origin form the first and second heart
fields (FHF and SHF, reviewed in Buckingham et al., 2005; Sri-
vastava, 2006). These fields, which can be distinguishedspatially as early as day E7.5 of mouse gestation, give rise to
either the majority of the left ventricle and parts of the atria or
the right ventricle plus parts of the atria and proximal part of
the great arteries, respectively. To date, there is no specific
marker of progenitor cells of the FHF, although expression of
Nkx2.5 identifies progenitor cell populations within both heart
fields of the developing heart (Wu et al., 2006). In the SHF,
a growing body of evidence shows that cardiac progenitor cells
express the LIM-homeodomain transcription factor Islet1 (Isl1)
(Cai et al., 2003; Laugwitz et al., 2005; Moretti et al., 2006). Iso-
lated Isl1-expressing cells can be purified, expanded, and differ-
entiated to all cell lineages of the heart. The molecular cues that
regulate this population are under investigation. To this end, Isl1
positive cardiac progenitor cells have been expanded in culture
by treatment with secreted ligands of the Wnt/b-catenin pathway
(Qyang et al., 2007). In addition to FHF and SHF progenitors,
recent work has identified epicardial progenitor cells, expressing
the transcription factors Wt1 and Tbx18, as yet another multipo-
tent cell type important for proper formation of a fully functioning
heart (Cai et al., 2008; Zhou et al., 2008a). Progeny from these
epicardial progenitor cells cover the surface of the heart, and
differentiated cardiomyocytes derived from these precursors
also appear to integrate into the myocardium of all four cham-
bers of the heart. Finally, some cells in the heart are of nonmeso-
dermal origin. During embryogenesis, neural crest cells delami-
nate from the neural tube and migrate ventrally, some of which
reach and populate the developing heart, intermixing with
cardiac progenitor cells of mesodermal origin. Cardiac neural
crest progenitor cells, identified by their expression of the tran-
scription factor Pax3, contribute to the outflow tract of the devel-
oping heart (Conway et al., 1997; Li et al., 1999), reviewed in
(Stoller and Epstein, 2005). The mature heart is a mosaic of cells
from these different progenitor populations (Figure 1).
Thus, in contrast to the situation in adult hearts, the biology
of cardiac progenitor cells in the developing embryo is compar-
atively well understood, with an established marker for multipo-
tent progenitor cells, identified molecular cues controlling their
expansion, and a well defined lineage tree showing their capacity
to give rise to all cellular lineages of the heart. However, there are
obvious ethical barriers to the use of such cells for transplanta-
tion. Access to embryonic cardiac tissue is only possible through
destruction of embryos, and fetal tissue will not be available in
sufficient amounts to supply the required number of cells.
In sum, for transplantation purposes, it would be ideal to focus
on a source of cells that combines the scalability of bone marrow
or satellite cells with the proven cardiogenic potential and estab-
lished cardiac lineage tree of cardiac progenitor cells present
during embryonic development.
ESCs, iPSCs, and Reprogramming
With this in mind, embryonic stem cells (ESCs) have emerged as
one of the most promising sources of cardiac cells for transplan-
tation purposes. Human ESCs (hESCs), first isolated 1998 by
James Thomson and co-workers from the inner cell mass of
preimplantation embryos (Thomson et al., 1998), are pluripotent
cells capable of differentiating into virtually every cell type,
including cells of the heart (Kehat et al., 2001). In the decade
following the isolation of hESCs, protocols to differentiate these
cells into cardiomyocytes have been refined (for review, seeCell Stem Cell 5, October 2, 2009 ª2009 Elsevier Inc. 367
Cell Stem Cell
ReviewPassier et al., 2006). Several groups have successfully isolated
cardiomyocytes or cardiac progenitor cells from differentiating
ESCs grown either in three-dimensional clumps termed
embryoid bodies or 2D cultures treated with various extracellular
proteins that increase the yield of cardiac cells. Importantly, the
ESC-derived cardiomyocytes not only share molecular markers
with primary cardiomyocytes, but ultrastructural (electron
microscopy), electrophysiological (action potential measure-
ments), and mechanical (determination of contractility) studies
of the ESC progeny indicate that they also exhibit all hallmarks
of cardiomyocytes. Of potential importance, ESC-derived cardi-
omyocytes have been shown to exhibit a phenotype reminiscent
of fetal, rather than adult, cardiomyocytes (Kehat et al., 2001;
Mummery et al., 2003). The reason for this phenomenon is not
known but deserves further investigation. Given the observed
differences between fetal and adult cardiomyocytes, ESC-
derived cardiomyocytes with features of adult cells would
probably be preferable for clinical transplantation purposes.
Nonetheless, ESC-derived cardiomyocytes have already been
used in transplantation experiments in rodent models of cardiac
disease (reviewed in Passier et al., 2008). These results show
that hESC-derived cardiomyocytes can couple electromechani-
cally with cardiomyocytes of the host, and beneficial effects in
myocardial infarction have been reported 4 weeks after trans-
plantation (Laflamme et al., 2007). However, in a study with a
longer follow up, no effect on cardiac function could be docu-
mented 12 weeks after transplantation (van Laake et al., 2007).
Thus, the long-term effects of ESC-derived cardiomyocytes to
injured myocardium need to be evaluated further.
Recently, a novel way of generating stem cells from differenti-
ated cells has been described. This technique, pioneered by
Shinya Yamanaka and colleagues, relies on the reprogramming
of fully differentiated cells to ESC-like cells, known as induced
pluripotent stem cells (iPSCs) (Takahashi and Yamanaka, 2006).
iPSCs exhibit the two key features of ESCs, in that they can be
expanded over many passages in vitro and give rise to cells of
all three germ layers, both under appropriate in vivo and in vitro
differentiation conditions. Originally established for mouse
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Figure 1. The Heart Is a Mosaic of Cells from
Different Progenitor Populations
The heart is composed of cells derived from at least
four different populations of progenitor cells—the
first heart field progenitor cells (blue), the second
heart field progenitor cells (red), the epicardial
progenitor cells (yellow), and the cardiac neural
crest progenitor cells (green). Progeny from these
progenitor pools reside in distinct but partly over-
lapping areas in the mature heart.
embryonic fibroblasts with a genetic
selection strategy for identifying reprog-
rammed cells, the basic iPSC derivation
protocol has been refined by many
groups, permitting reprogramming of
human cells (Park et al., 2008; Takahashi
et al., 2007; Yu et al., 2007), reprogram-
ming without genetic selection (Blelloch
et al., 2007; Meissner et al., 2007), and
chemicals enhancing reprogramming
efficiency (see Yamanaka, 2009 for review). This body of work
has propelled iPSC technology to the forefront of experimental
regenerative medicine. Being derived from adult cells, iPSCs
bypass the ethical issues regarding the use of embryonic human
tissue to cure disease, and immunocompatibility is not an issue
because the starting material, skin fibroblasts, can be obtained
from the patient. However, there are currently caveats with the
iPSC reprogramming procedure that need to be addressed
before this elegant technology can be put to clinical use. One
important aspect is that the original protocol for reprogramming
of human cells to iPSCs relies on the use of viruses integrating
into the genome of cells undergoing the reprogramming pro-
cess. Clinical trials in gene therapy have shown that integration
of viruses in tumor-suppressor genes may give a selective
advantage and thereby promote malignancy when transplanted
to the patient (Hacein-Bey-Abina et al., 2003; Ott et al., 2006).
Moreover, given that some of the virally encoded genes are
oncogenes that may be reactivated after transplantation, it is
clear that protocols permitting reprogramming without the use
of viruses are essential before iPSCs can become a clinical
tool. Very recently, it has been shown that human iPSC deriva-
tion can be achieved with transposon (Kaji et al., 2009; Woltjen
et al., 2009), episomal (Yu et al., 2009), and direct protein delivery
(Kim et al., 2009) systems, and it will be interesting to compare
whether iPSCs generated by these methods are equivalent to
iPSCs generated with integrating viruses. Furthermore, the
long-term performance of differentiated cells derived from iPSCs
needs to be critically assessed. In this regard, a detailed compar-
ison between cardiomyocytes derived from iPSCs and cardio-
myocytes derived from ESCs is required before iPSCs can be
considered for regenerative therapy in cardiology.
Even with an efficient method for nonviral iPSC generation of
human cells in place, and even if iPSCs prove to be functionally
equivalent to human ESCs, there is still one potentially important
drawback with the iPSC technology—the time iPSC derivation,
with stringent criteria for pluripotency and capacity to differen-
tiate to the lineage of interest, requires (reviewed in Maherali
and Hochedlinger, 2008), which would at least be relevant for368 Cell Stem Cell 5, October 2, 2009 ª2009 Elsevier Inc.
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ment is in sharp contrast to banked hESCs, which would be rela-
tively easy to expand, store, and distribute in an off-the-shelf
paradigm. For use of iPSCs in a similar manner, banks of pre-
tested pluripotent cell lines would have to be established.
Although still in its infancy, it appears likely that cellular reprog-
ramming may provide important tools for translational scientists
aiming at generating a specific cell type for cell therapy. In addi-
tion to the iPSC technology, where fully differentiated cells are
reprogrammed to the fully undifferentiated ESC-like state, and
subsequent differentiation of such cells can give the desired
cell type, one can envision more direct ways of reprogramming
cells. In a pioneering experiment conducted more than 20 years
ago, Harold Weintraub and colleagues showed that forced
expression of the myogenic transcription factor MyoD in cultured
fibroblasts caused such cells to adopt the myocyte fate (Davis
et al., 1987). Thus, it seemed plausible that at least some cells in
the body may have a more plastic developmental identity than
traditionally thought. Recently, Douglas Melton and colleagues
have taken this concept one step further. By first establishing
the transcriptional code for generation of endocrine, insulin-
producing beta cells in the pancreas during embryonic develop-
ment (Zhou et al., 2007) and thereafter transducing exocrine cells
with viruses expressing these factors (Zhou et al., 2008b), they
showed that cellular reprogramming can be achieved not only
in the Petri dish but also in vivo. More importantly from a transla-
tional point of view, it also established that such reprogramming
can be beneficial for the organism, in this case by improving the
glucose-controlled secretion of insulin in a mouse model of
diabetes mellitus through generation of new beta cells (Zhou
et al., 2008b).
It remains to be seen how broadly applicable the ‘‘transdiffer-
entiation by reprogramming’’ approach will be. Even if cells in
other organs such as the heart may be less susceptible to trans-
differentiation, it is possible that modifications of the iPSC pro-
tocol may be beneficial. For example, one could envision reprog-
ramming exogenous cells such as fibroblasts to a relatively
restricted mesodermal or cardiac-restricted progenitor stage,
rather than all the way to pluripotent iPSCs. This approach would
make subsequent differentiation and purification procedures
considerably less challenging and minimize the risk of trans-
planting unwanted and potentially dangerous contaminating
cells. Furthermore, identification of the factors controlling lin-
eage decisions of progenitor cells can facilitate the generation
of defined populations of fully differentiated progeny. In this re-
gard, forced expression of intrinsic fate determinants has proven
to be an efficient method for generating dopaminergic neurons
from ESCs and neural progenitor cells (Andersson et al., 2006),
and more recently similar approaches have been shown to be
fruitful also in the cardiac lineage (David et al., 2008; Takeuchi
and Bruneau, 2009).
Purification
Two critical steps will be needed to determine whether progen-
itor cells or differentiated cardiomyocytes will be preferable for
transplantation purposes and how to purify this population
from a heterogenous culture of differentiating ESCs or iPSCs.
To date, several published reports describe transplantation of
differentiated cardiomyocytes derived from human ESCs torodents (for review, see Passier et al., 2008). Alternatively, using
a pure population of restricted cardiac progenitor cells may yield
a transplanted population with a higher expansion capacity,
thereby potentially increasing substantially in number after suc-
cessful engraftment. This benefit may represent an important
advantage given the large number of cells that are to be re-
placed. Another advantage is that cardiac progenitor cells are
able to form endothelial cells, which might result in improved
vascularization of the resulting graft. However, controlling the
generation of mature, fully differentiated cells from grafted
progenitors will be both important and challenging, and more
basic research to uncover the molecular mechanisms underlying
cardiac progenitor cell differentiation is warranted.
Isolation and expansion of desired progenitor cells, such as
cardiomyocytes or cardiac progenitor cells, have generally
been accomplished by transgenic labeling of the desired cell
type, followed by antibiotic selection, or by purification with
cell-sorting techniques. Although highly efficient and of immense
importance for research purposes, genetic manipulation of the
starting cellular material is generally not considered compatible
with the production of clinical-grade cells. The identification of
cell-surface markers, enabling antibody-based identification
and purification of cells for transplantation, will be an important
step in bringing stem cell-based cardiology closer to the clinical
setting. On the other hand, it is paramount to exclude all
unwanted, more primitive cells from the material to be trans-
planted, and it remains to be proven whether antibody-based
protocols for isolation of a cell population entirely devoid of
contaminating ESCs can be developed (Kiuru et al., 2009). It is
possible that some forms of genetic labeling will have to be
accepted to ensure the purification of a clinically safe population
of cells.
Delivery
Recent clinical studies have also clearly identified the need for
improved in vivo cell delivery systems to the heart and other
tissues. Of the solid organs in which cell therapy has been
considered, the heart is unique in that repeated and frequent
movement of the organ, resulting in changing pressures and
geometry inside the heart, is paramount for life. Thus, it is not
trivial to transplant cells to an exact location in the heart and
make them stay there. Experiments in rodents have shown that
delivery of cells to infarcted myocardium is inefficient. In one
published report, as few as 15% of transplanted cells stayed in
the heart, whereas the rest of the transplant leaked out either
through the injection site or into the recipient’s circulation
(Muller-Ehmsen et al., 2002). In addition, retention of cells at
the site of injection varied widely between hosts, making it very
difficult to predict the size of the heart graft following transplan-
tation.
The challenge of poor graft retention may be circumvented
by minimizing cell leakage from the injection site, such as by
embedding cells in a viscous polymer prior to transplantation
(Laflamme et al., 2007). Another attractive possibility would be
to engineer contractile cardiac tissue ex vivo into a multilayered
graft that can both provide support to the failing heart and be
handled surgically as a single piece during transplantation.
Efforts in tissue engineering with neonatal cardiomyocytes
have provided patches of cardiac tissue that integrateCell Stem Cell 5, October 2, 2009 ª2009 Elsevier Inc. 369
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cardiac function when grafted to infarcted rat hearts (Zimmer-
mann et al., 2006). Moreover, recipient blood vessels derived
from the surrounding tissue grew into the graft, ensuring the
proper supply of oxygenated blood. This is an important finding,
given that the size of the implant precluded a sufficient supply of
nutrients by passive diffusion from surrounding blood vessels
alone. Other reports of successful tissue engineering of interest
for regenerative cardiology include the possibility of generating
anisotropic sheets of cardiomyocytes on thin film substrates
ex vivo (Feinberg et al., 2007). In sum, these approaches illus-
trate the feasibility and power of tissue engineering in regenera-
tive medicine and the use of purified cardiomyocytes or cardio-
myocyte-restricted precursor cells derived from ESCs as a
cellular source. In the future such experiments may enable the
generation of stem cell-derived grafts for cardiac surgery, which
may complement other strategies to restore cardiac function
through cellular therapy (summarized in Figure 2).
Cell Survival and Suppression of Rejection
Yet another challenge associated with cell transplantation is the
fact that the majority of transplanted cells that manage to stay in
the heart will not survive. In fact, it has been estimated that
almost nine out of ten transferred cells will eventually die (La-
flamme and Murry, 2005; Muller-Ehmsen et al., 2002). Several
methods to increase cell survival have been described, including
heat shock of the cells prior to transplantation, forced expression
of survival factors in the transplanted cells, and exposure of the
transplant to soluble prosurvival factors (Laflamme et al., 2007).
Although these interventions do seem to increase cell survival,
there is clearly room for additional improvement. We still do
not have a complete understanding of the mechanisms causing
the massive cell death of transplanted cells, and it is likely that
insights into these processes will provide novel approaches to
increase the survival of cells transplanted to the myocardium.
Additionally, ESCs are foreign to the body and may cause
immunological reactions directed against the graft. This risk
can be overcome by immunological typing of the cells prior to
Isolation
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Bone marrow-derived cells
Fibroblasts
iPS derivation
Restricted progenitors /
Mature cardiomyocytes
Delivery
Surgical implantation
Intracoronary
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Transdiﬀerentiation Directed diﬀerentiation
Pluripotent cells ESCs
Figure 2. Experimental Approaches
to Cardiac Cell Therapy
Clinical trials have been conducted with satellite
cells and preparations of bone marrow cells, that
have been delivered to the failing heart. Such treat-
ments have failed to increase the number of cardi-
omyocytes in the heart. Conceptually this would
be possible to achieve by purifying cells of the
cardiac lineage from differentiating ESCs or iPSCs,
or by direct reprogramming of somatic cells to the
relevant cell type, and thereafter transplanting
such cells to the heart of the patient.
grafting and with immunosuppressive
therapy. Patient-specific iPSCs offer, in
contrast to established ESC lines, an au-
tologous source of pluripotent stem cells,
thereby bypassing all issues regarding
immunological incompatibility. On the
other hand, in cases where heart failure
is due to a mutation resulting in cell-
autonomous dysfunction of cardiomyocytes, such as hereditary
forms of cardiomyopathy, cardiac cells derived from patient-
specific iPSCs will carry the same disease-causing mutation.
In such cases, correction of the disease allele will be required
prior to transplantation. The feasibility of this approach has
already been shown in a mouse model of sickle cell anemia, in
which iPSC derivation, correction of the disease-causing muta-
tion by gene targeting in vitro, and subsequent transplantation
of hematopoietic progenitor cells derived from such ‘‘corrected’’
iPSCs cured the disease (Hanna et al., 2007).
Grafting, Integration and Alignment
of Transplanted Cells in the Recipient Heart
To enhance the pumping capacity of the failing heart, trans-
planted cells must not only remain in the heart after transplanta-
tion and survive, they must also integrate into the native cardiac
tissue. How individual differentiated cells come together to form
the three-dimensional structure of the heart is the perhaps most
poorly understood area of cardiogenesis. During embryonic
development, cardiomyocytes elongate, align, and orient in a
linear fashion. In addition, cardiomyocytes are subsequently
coupled to each other in an end-to-end fashion by intercalated
discs. These specialized structures, containing gap junction
proteins, facilitate the spreading of the electrical impulse from
one fiber of cardiomyocytes to another. Moreover, layers of
fibers are aligned to form an anisotropically oriented basket
weave of muscle. Thus, the distinct cellular architecture of
contractile tissue permits two key features of the physiology of
the ventricular myocardium: rapid and coordinated spreading
of the electrical impulse controlling the frequency of the heart
beat, and a coordinated contraction resulting in pumping of
blood from the heart throughout the tissues of the organism.
To improve cardiac function, transplanted cells have to align,
engraft, and couple with the myocardium of the host in an
ordered fashion. How this organization is orchestrated is not
known, but published transplantation experiments show that
integration does occur, raising the probability that extracellular
matrix or resident cells in the adult heart provide directional370 Cell Stem Cell 5, October 2, 2009 ª2009 Elsevier Inc.
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cells. Strikingly, a recent publication demonstrated that a prepa-
ration of cardiomyocytes repopulated a decellularized heart ex
vivo and aligned to form a beating myocardium (Ott et al., 2008).
Pathology of the heart results in disorganization of cardiac
tissue and disruption of its intricate electromechanical propor-
ties. Fibers of cardiomyocytes are lost or become separated
by fibrous scars, and individual fibers lose directional orientation
and emanate at an angle from correctly, anisotropically oriented
fibers. In addition, cell types not normally present in the heart
may invade the cardiac tissue in response to injury. For example,
the onslaught of a myocardial infarction results in recruitment of
several hundreds of millions of leukocytes and lymphocytes,
secreting important mediators of inflammatory and immune
responses. Furthermore, the infarcted area may still be in a rela-
tively hypoxic state due to the injured vessels responsible for
supplying the area with oxygen. It is in such a molecularly inhos-
pitable mileu that transplanted cells are expected to graft, prolif-
erate and differentiate, integrate, survive, and increase the
pumping capacity of the heart. Not surprisingly, it has been
documented that transplanted ESC-derived human cardiomyo-
cytes do not graft as efficiently into infarcted heart tissue
compared to healthy myocardium (Laflamme et al., 2007),
arguing for a loss of cues driving their survival, alignment, and
electromechanical integration in the injured myocardium. How
to deliver oxygen and nutrients to the grafted cells will be
a very important issue, and it will be key to understand how blood
vessels present in the heart can be coaxed to invade the layer of
transplanted cardiomyocytes. As discussed above, engineering
larger grafts of myocardium ex vivo for surgical implantation may
prove to be an alternative option to injection of single-cell
suspensions into the damaged myocardium. Given that larger
grafts will need more oxygen and nutrients than what can
passively diffuse from the host circulation, it may prove fruitful
to develop vascular structures ex vivo to be delivered in concert
with the rest of the graft.
Side Effects
All forms of medical treatment are accompanied by the risk of
unwanted side effects. Stem cell-based therapy is no exception,
and there are several potential side effects associated with
transplantation of cardiac progenitor cells to the ailing heart.
The most obvious, immediate concern for any transplant of
ESC/iPSC-derived populations is the risk of teratoma formation.
Teratomas are tumors composed of a random mixture of dif-
ferent cell types derived from contaminating, undifferentiated
ESCs inadvertantly present among the transplanted cells
(Lensch et al., 2007). Although teratomas are benign, it is self
evident that a growing mass of random tissue inside the ventric-
ular myocardium will be detrimental to cardiac function (see
Laflamme and Murry, 2005 for review). Thus, as discussed
above, a sorted population of developmentally restricted,
cardiac-specific cells, devoid of any contaminating undifferenti-
ated ESCs, is paramount for a positive outcome when using
ESC-derived cells therapeutically.
In addition to the risk of teratomas, there are other conceivable
side effects more specific to the heart. Here, the problem is not
defective differentiation but rather defective function of the
grafted cells caused by improper electromechanical integrationwith the myocardium of the host. This defect generally manifests
as dysfunction in contraction. Arrhythmias may occur when the
transplanted cells are integrated into the cardiac syncytium but
exhibit uncoordinated electrical activity out of sync with cells
of the recipient heart. The result could be ectopic pacemaker
activity in the ventricular tissue, causing dysynchronous electri-
cal stimulation and therefore inefficient mechanical contraction.
Another potential side effect is dyskinesia, in which the grafted
cells are not integrated into the rhythmic contraction of the
host myocardium but survive after transplantation as an isolated
segment of cardiac cells, exhibiting its own frequency of
contraction. The graft will thereby perform independently of,
and in the worst scenario work against, the cardiac tissue of
the recipient. Thus, although principally different, the outcome
in both cases will be dysfunction of an already impaired heart.
It is important to note that an early clinical trial in which skeletal
myoblasts were transplanted to postischemic hearts resulted
in arrhythmia in several patients (Menasche et al., 2003).
Toward Regenerative Cardiovascular Medicine for
Pediatric Heart Disease: Challenges and Opportunities
Congenital heart disease is the most common birth defect,
affecting one out of every one hundred live births. Many lesions
are life threatening and require surgical correction, often within
the first week of life. The challenges faced by the care of patients
with congenital heart disease are altogether different from
acquired adult heart disease. Surgical restoration of normal
biventricular circulation is necessary in many malformations.
During the repair of many defects, it is necessary to implant
exogenous material in the heart from an extracardiac source.
For closure of atrial or ventricular septal defects, several different
materials are often used including autologous pericardium,
bovine pericardium, or Gore-tex. These materials are ideal for
this purpose because they serve as a barrier to blood flow but
do need to functionally couple to the surrounding tissue. On
the contrary, other conditions require more extensive extracar-
diac material whose current properties are not ideal and offer
an opportunity for stem cell-based tissue engineering solutions.
Additionally, stem cell technology is expanding our under-
standing of the etiology of complex congenital heart disease
by advancing the creation of human and murine in vitro models
of cardiac development.
With lineage tracing, an early primordial ISL1 human heart
progenitor cell has been recently identified in a human ESC
system, which gives rise to a well-characterized family of down-
stream multipotent SHF heart progenitor cells that then generate
diverse lineages (Bu et al., 2009). In the mouse, there is a rapid
transition from Isl1 expression to migration and conversion to
differentiated progeny in cells of the SHF. At later embryonic
stages, few Isl1-expressing cells can be found in the heart,
including the developing outflow tract. Moreover, Isl1-express-
ing cells generally coexpress markers such as Flk-1 and Nkx2.5,
possibly reflecting a rapid fate restriction, whereas human
cardiogenesis is a much longer process. ISL1-expressing cells
that do not express other markers such as FLK-1 or NKX2.5
are found in the developing heart including the outflow tract,
which may represent the upstream precursor for the family of
multipotent progenitors in the SHF lineage (Bu et al., 2009).
Acquisition of the fully differentiated state takes longer for humanCell Stem Cell 5, October 2, 2009 ª2009 Elsevier Inc. 371
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restricted progenitors presumably reflect the need for cellular
expansion due to the orders of magnitude in size that distinguish
adult mouse and human hearts (Table 2). Additionally, the iden-
tification of ISL1-expressing intermediates in the outflow tract
during later-stage human cardiogenesis suggests the renewal
of this population may play a pivotal role in expanding the tissue
mass of diverse lineages. These same compartments are known
to be defective in multiple forms of severe human congenital
heart disease. If defective renewal of these cells is at fault in these
cases, a ‘‘stem cell paradigm’’ may be responsible for the onset
of an important subset of outflow tract diseases. In this regard,
many of the known monogenic causes of human congenital heart
disease are known to affect cell-fate decisions in the islet lineage,
and further direct testing of this concept is warranted (Figure 3).
One important translational outcome of these studies is the clear
identification of a purified and clonable source of human heart
progenitors that can serve as in vitro models of human complex
congenital heart disease. Future studies extending the work into
the context of iPSCs might offer the possibility of generating
tissue engineering solutions to generate grafts that can then be
populated by in vitro-derived cells.
An example of the potential for tissue-engineering applications
is surgical replacement or reconstruction of the semilunar valves
Table 2. Comparison of Outflow Tract Development in Humans
and Mice
Mouse Human
Gestational length 3 weeks 9 months
Time for outflow tract formation days weeks
Size of adult heart 1 3 0.5 30.3 cm 13 3 8 3 5 cm
Weight of adult heart 110 mg 300 g
During early embryogenesis, the size differences between the human and
mouse embryo are relatively modest. From a relatively similar size when
beating commences, the difference in size between human and mouse
hearts increase rapidly during later stages of embryonic and postnatal
development, implying a higher degree of progenitor proliferation in
human cardiogenesis.and proximal great arteries of the heart. In some congenital
lesions such as pulmonary atresia, truncus arteriosis, and
pulmonic replacement after Ross procedure, de novo recon-
struction of the right ventricular outflow tract and pulmonary
valve is necessary (Figure 4). Surgeons have a variety of options
but two of the most commonly used right ventricular to pulmo-
nary artery (RV-to-PA) conduits are frozen cadaveric human
tissue (homograft) or valved bovine jugular vein (Contegra Xeno-
graft). Despite the many successful outcomes these types of
materials have provided, there is additional room for improve-
ment. Unlike native vessels, grafts have no capacity for growth,
necessitating upsizing as the hemodynamic needs of the child
increase. Additionally, these grafts represent immunologic
foreign material and are attacked by the patient, leading to accel-
erated sclerosis, calcification, and often obstruction of these
conduits and the conduit valve. A typical child needing an
RV-to-PA conduit in infancy will need at least one to two addi-
tional surgeries, with full cardiopulmonary bypass, to upsize
the conduit before age 20, not to mention numerous catheteriza-
tion procedures aimed at balloon dilating or stenting open these
conduits.
An ideal conduit material would be appropriately scaled to the
patient, have capacity for growth, and evade immune surveil-
lance. Recent advances in stem cell biology allow researchers
to imagine the construction of replacement grafts composed of
material grown from the patient. Pioneering researchers have
made great strides toward this outcome by using animal models
and cells from animal and human umbilical cord donor and more
recently, with bone marrow-derived cells (Hoerstrup et al., 2002;
Mettler et al., 2008; Shieh and Vacanti, 2005; Shinoka et al.,
1998). Alternatively, ESC or iPSC technology could be used to
produce pluripotent cells and then direct differentiation of these
cells into appropriate cardiovascular lineages (Figure 4). The
cells generated via this approach could be not only the correct
cell type (smooth muscle) but additionally of proper embryonic
lineage (SHF) to assure functionality. In cases involving genetic
defects, strategies aimed at fixing any known genetic defects
within patient-derived iPSCs would need to be employed. Ap-
plying this therapeutic paradigm will require tissue-engineeringISL1+ expansion
ISL1+ differentiation
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Figure 3. Schematic Illustration of Cardiac
Outflow Tract Development and Its Relation
to Congenital Heart Disease
The outflow tract is derived largely from SHF
progenitor cells with more distal contributions
from cardiac neural crest. Disturbances in the
proliferation and differentiation of ISL1-expressing
progenitor cells disrupt developmental morpho-
genic functionality and cause malformations of
the outflow tract seen in patients with congenital
heart disease (blue arrows). Several genes, when
mutated, are known to cause these prototypical
outflow tract malformations: double outlet right
ventricle (NKX2.5, THRAP2, and CHD7), transposi-
tion of the great arteries (NKX2.5, GDF1 and
CHD7), persistent truncus arteriosus (NKX2.5,
TBX1, NOTCH1 and NOTCH2, JAGGED1, GDF1,
THRAP2, and CHD7), and aortic stenosis (NOTCH1).
A-P, aorto-pulmonary.
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Figure 4. Ex Vivo Construction of ESC-Derived RV-PA Conduit
Implantation of a conduit to substitute for an atretic great artery is needed for several different congenital lesions including pulmonary atresia. Combining
advances in ESC or iPSC technology to derive SHF-specific vascular smooth muscle cells with described tissue-engineering solutions could provide proper
lineage-derived conduits with growth capacity.solutions to provide seeded cells with relevant form and function.
For a conduit graft, a vascular scaffold with or without valve
apparatus will be needed, and this scaffold can then be popu-
lated by in vitro-derived cells. This type of scaffold could be
engineered either de novo (Shieh and Vacanti, 2005) or by the
decellularization-recellularization of tissue from human cadavers
or other large mammals as an underlying matrix scaffold, as
demonstrated with rat heart (Ott et al., 2008).
Importantly, although the discussion above is focused on
comparatively rare congenital defects, the same bioengineering
challenges are also applicable to more commonly acquired
cardiovascular diseases. Tissue-engineering attempts will
become increasingly common as the ability to make patient-
specific cells from defined embryologic lineages improves and
becomes more efficient. In short, advances in stem cell biology
have helped transition dreams of certain medical applications
from science fiction-like concepts toward realistic discussions
of engineering organs ex vivo for specific disease interventions.
Lessons from the Bone Marrow
Overall, it seems clear that the aim to bring stem cells to clinical
practice in the field of cardiology is a noble, worthy, but also
challenging if not daunting goal. However, a comparison with
the path taken in hematology, the field of clinical medicine in
which stem cell biology already has had an enormous impact,
may be both instructive and enlightening. Stem cell therapy in
the form of bone marrow transplants have been used clinically
for more than half a century, with the first successful procedure
conducted by E. Donnall Thomas in the 1950s. Here, Thomas
cured a patient with leukemia by first subjecting him to total-
body irradiation and thereafter injecting bone marrow from thepatient’s identical twin, who did not have leukemia (Thomas
et al., 1959; Thomas et al., 1957). At first glance, this initial indi-
cation for bone marrow transplant—cancer, characterized by
uncontrolled cellular proliferation—is very different from heart
failure, in which the loss of cardiomyocytes typically causes
disease. However, the cancerous cells were killed by the irradi-
ation procedure, and the role of the transplanted bone marrow
was to replace the recipient’s own bone marrow, which was
lost during the radiation therapy. Subsequently, bone marrow
transplantation was used also in disorders characterized by
a deficiency of a particular hematopoietic cell type. The first non-
cancer bone marrow transplants took place in 1968, this time to
cure a boy with severe combined immunodeficiency disorder by
transplant with marrow from his sister (Gatti et al., 1968).
However, in the first two decades, the hematology field was
hampered by graft-versus-host disease (GVHD), a phenomenon
known already prior to Thomas’s pioneering work. It was recog-
nized that during GVHD, grafted cells produce an immune reac-
tion against host tissues (Billingham and Brent, 1957). So that
GVHD could be avoided, bone marrow had to be obtained
from a close relative, ideally an identical twin as in Thomas’s
initial transplant procedure. However, it was the unraveling of
our core understanding of the control of the human immune
system that represented the breakthrough required for bone
marrow transplantation to become standard clinical therapy.
As the field of immunology progressed, manifested by the iden-
tification of the major histocompatibility complex and how it
regulates immunological reactions (chronicled in Marx, 1980),
the molecular basis of GVHD was ultimately elucidated. This
finding in turn opened up the possibility of reducing the risk of
GVHD by performing HLA haplotype matching between donorCell Stem Cell 5, October 2, 2009 ª2009 Elsevier Inc. 373
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transplants in which donor and recipient were unrelated, which
first occurred in the 1970s (reviewed in Thomas et al., 1975).
Since then, advances in immunosuppressive therapy have
been important in further minimizing the risk of GVHD, and autol-
ogous bone marrow transplant has become an option for several
diseases.
The chain of events outlined above can serve as an inspiring
template for researchers in the fields of translational stem cell
biology and regenerative medicine. To establish bone marrow
transplantation as a clinical treatment, pioneers of the field had
to identify ways to improve grafting (irradiation of the host,
thereby escaping an immune response to the graft by host cells)
and the most common side effects (HLA haplotyping to ensure
immunologically matched transplants to avoid GVHD). Similarly,
by identifying problems that need to be solved and addressing
them in appropriate model organisms in a tenacious, innovative,
and rigorous fashion holds great promise for the burgeoning field
of regenerative medicine for heart disease and many other
chronic conditions. For stem cell biology, regeneration is next,
and an exciting future belongs to a next generation of physicians
and scientists working together as a team on this central
problem in modern human biology and medicine.
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